Liraglutide
Liraglutide for Diabetes Control
A proven therapy for improving blood sugar levels in type 2 diabetes.
Liraglutide for Weight Loss
Clinically effective in supporting long-term sustainable weight loss.
Liraglutide's Health Benefits
Enhancing glycemic control and promoting overall metabolic health.
Advancing Liraglutide Treatment
Partner with us to improve patient outcomes in diabetes and obesity.
Pal-Glu(OSu)-OtBu
Pal-Glu(OSu)-OtBu, or Nε-palmitoyl-L-glutamic acid γ-succinimide-α-tert-butyl ester, is an essential intermediate used in the synthesis of liraglutide, a long-acting GLP-1 receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes. This compound plays a key role in the creation of lipid-conjugated derivatives of GLP-1 that enhance the pharmacokinetic properties of the peptide, providing sustained action and improving therapeutic efficacy.
Pal-Glu(OSu)-OtBu is widely utilized in the synthesis of lipidated peptides designed for weight management and diabetes treatment. The palmitoyl group at the Nε position facilitates increased stability and enhances the compound’s affinity for target tissues, promoting prolonged biological activity. As part of liraglutide synthesis, it is critical for the development of obesity and type 2 diabetes treatments that benefit from the extended-release characteristics of the drug.
CAS No: 204521-63-1
>>Download COA
Application:
- Peptide Synthesis: Used in the preparation of lipid-conjugated GLP-1 analogs for diabetes treatment.
- Pharmaceutical Development: Essential in the synthesis of liraglutide, a GLP-1 receptor agonist with long-acting effects.
- Weight Management: Used in the development of pharmaceutical formulations targeting obesity and weight loss.
- Biochemical Research: Investigated for its role in modifying the pharmacokinetics of peptide-based therapeutics.
Storage condition: Hygroscopic, refrigerator, under inert atmosphere.
Packing: Customized
Need more information/samples?